profit from every $100 of sales.
$0$100
IQVIA Holdings
$271.11-1.25% today
+22.7% in 1 year
1-year low $156.661-year high $279.36
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $32.85 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What IQVIA Holdings sold, what it kept, and what it did with the cash.
Sales went from $14.4 billion in 2022 to $16.3 billion in 2025, with $1.36 billion of profit last year.
SalesProfit
IQVIA Holdings handed back 61% of the cash it generated last year.
Buybacks $1.2B
Free cash flow 2025$2.1B
Bought back its own shares$1.2B
Paid as dividends–
Cash vs. debt$2.0B vs. $15.9B
IQVIA Holdings vs. similar companies
IQVIA Holdings grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| IQVIA Holdings | 32.9× · Expensive | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.2× · Expensive | ||
 Waters | 141.4× · Very expensive | ||
 WuXi AppTec | 27.1× · Fair price |
Compare IQVIA Holdings with Incyte
AI analysis
An AI analyst reads IQVIA Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 11,359 | 13,874 | 14,410 | 14,984 | 15,405 | 16,310 | |
| – | – | 5,028 | 5,239 | 5,375 | 5,430 | |
| 731 | 1,393 | 1,827 | 2,061 | 2,269 | 2,287 | |
| 2,076 | 2,767 | 2,909 | 3,256 | 3,453 | 3,464 | |
| 279 | 966 | 1,091 | 1,358 | 1,373 | 1,360 | |
| 1.43 | 4.95 | 5.72 | 7.29 | 7.49 | 7.84 | |
| – | – | 34.9% | 35.0% | 34.9% | 33.3% | |
| 6.4% | 10.0% | 12.7% | 13.8% | 14.7% | 14.0% | |
| 2.5% | 7.0% | 7.6% | 9.1% | 8.9% | 8.3% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 24,564 | 24,689 | 25,337 | 26,681 | 26,899 | 29,944 |
| Cash | 1,814 | 1,366 | 1,216 | 1,376 | 1,702 | 1,980 |
| Total debt | 13,060 | 12,578 | 13,011 | 13,896 | 14,156 | 15,949 |
| Total liabilities | 18,284 | 18,647 | 19,572 | 20,569 | 20,832 | 23,314 |
| 6,001 | 6,042 | 5,765 | 6,112 | 6,067 | 6,503 | |
| 195 | 195 | 191 | 186 | 183 | 174 | |
| 3.3% | 6.4% | 7.5% | 8.4% | 9.1% | 8.2% | |
| 4.6% | 16.0% | 18.9% | 22.2% | 22.6% | 20.9% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,959 | 2,942 | 2,260 | 2,149 | 2,716 | 2,654 | |
| 616 | 640 | 674 | 649 | 602 | 603 | |
| 1,343 | 2,302 | 1,586 | 1,500 | 2,114 | 2,051 | |
| Dividends paid | – | – | – | – | – | – |
| 447 | 406 | 1,168 | 992 | 1,350 | 1,244 | |
| 95 | 170 | 194 | 217 | 206 | 247 |
Valuation
- 32.9×
- 21.3×
- 0.81
- 6.9×
- 2.7×
- 21.8×
- 16.9×
- 4.6%
- 3.0%
- 0.0%
Profitability
- 33.3%
- 14.0%
- 8.3%
- 21.1%
- 28.9%
- 13.6%
- 22.5%
- 4.7%
- 10.8%
- –
Growth
- +7.5%
- +40.5%
- −3.0%
- –
- −3.1%
Financial health
- 4.0×
- 0.33
- 7.0%
- 3.2×
- 0.75
- 0.75
- 0.56
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 3%of 957
Top 38%of 889
Bottom 38%of 601
Bottom 39%of 884
Top 25%of 986
What analysts expect
- Average price target
- $225.63
- Range
- $185.00 – $250.00
- 9 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 2.90 | 2.83 | +2.5% |
| Feb 5, 2026 | 3.42 | 3.40 | +0.6% |
| Oct 28, 2025 | 3.00 | 2.98 | +0.7% |
| Jul 22, 2025 | 2.81 | 2.77 | +1.4% |
| May 6, 2025 | 2.70 | 2.63 | +2.7% |
| Feb 6, 2025 | 3.12 | 3.11 | +0.3% |
| Oct 31, 2024 | 2.84 | 2.82 | +0.7% |
| Jul 22, 2024 | 2.64 | 2.56 | +3.1% |
News
IQVIA Holdings Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 27, 2026IQVIA Q3 2026 Earnings PreviewSeeking Alpha · Oct 26, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
39No pass
Philip Fisher
61Pass
Peter Lynch
81Pass
Joel Greenblatt
35No pass
Charlie Munger
57No pass
Terry Smith
54No pass
Questions about IQVIA Holdings
Is IQVIA Holdings a good stock to buy?
A business with weak numbers, but the price is high. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the IQVIA Holdings AI analysis
What does IQVIA Holdings do?
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It is in Diagnostics & Research, based in Durham, NC, United States, with 93,000 employees.
Does IQVIA Holdings pay a dividend?
No. IQVIA Holdings does not pay a dividend at the moment; in 2025 it returned $1.24 billion to shareholders by buying back its own shares.
Is IQVIA Holdings stock halal?
No. IQVIA Holdings does not pass our halal screen: its debt is 36% of its market value, at or above the 33% limit. How we check
How has IQVIA Holdings stock done over the past year?
Up 22.7% over the past twelve months, to $271.11. It traded between $156.66 and $279.36 and is 3.0% below its high.
Who are IQVIA Holdings's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with IQVIA Holdings's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.